This site is intended for healthcare professionals
News

IDMC recommends early halt of phase III SANET-p study of HMPL 012 in neuroendocrine tumors – pancreatic.- Hutchison China MediTech

Read time: 1 mins
Published:21st Jan 2020
Hutchison China MediTech Limited announced that the independent Data Monitoring Committee of the Phase III pivotal study of HMPL 012 (surufatinib) in advanced neuroendocrine tumors – pancreatic (“SANET-p”) has completed a pre-planned interim analysis. The IDMC recommended that the study stops early as the pre-defined primary endpoint of progression free survival had already been met. Following the early success of this study, Chi-Med now plans to arrange a pre-New Drug Application meeting with the China National Medical Products Administration to discuss the preparation of the NDA for surufatinib for this indication. Chi-Med intends to submit the results of the SANET-p study for presentation at an upcoming scientific conference. Comment: SANET-p is a Phase III study in China of surufatinib in patients with low-grade or intermediate-grade advanced pancreatic neuroendocrine tumor patients for whom there is no effective therapy. In this study, patients are randomized at a 2:1 ratio to receive either 300 mg of surufatinib orally daily or placebo, on a 28-day treatment cycle.
Condition: Neuroendocrine Tumour/Pancreatic
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.